Trial · NCT03320850
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day | Stage 2: Placebo + Hydrogel Admixture | -2.72 | Standard Error 0.534 | episodes per day | |
| Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day | Stage 2: BOTOX® 100U + Hydrogel Admixture | -1.62 | Standard Error 0.539 | episodes per day | |
| Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day | Stage 2: BOTOX® 300U + Hydrogel Admixture | -0.89 | Standard Error 0.521 | episodes per day | |
| Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day | Stage 2: BOTOX® 400U + Hydrogel Admixture | -1.52 | Standard Error 0.520 | episodes per day | |
| Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day | Stage 2: BOTOX® 500U + Hydrogel Admixture | -1.85 | Standard Error 0.530 | episodes per day | |
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period | Stage 1: Placebo + Hydrogel Admixture | 6 | Participants | ||
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period | Stage 1: BOTOX® 100U + Hydrogel Admixture | 4 | Participants | ||
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period | Stage 1: BOTOX® 300U + Hydrogel Admixture | 4 | Participants | ||
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period | Stage 1: BOTOX® 400U + Hydrogel Admixture | 10 | Participants | ||
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period | Stage 1: BOTOX® 500U + Hydrogel Admixture | 6 | Participants | ||
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period | Stage 2: Placebo + Hydrogel Admixture | 25 | Participants | ||
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period | Stage 2: BOTOX® 100U + Hydrogel Admixture | 30 | Participants | ||
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period | Stage 2: BOTOX® 300U + Hydrogel Admixture | 30 | Participants | ||
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period | Stage 2: BOTOX® 400U + Hydrogel Admixture | 38 | Participants | ||
| Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAEs) in the Treatment Period | Stage 2: BOTOX® 500U + Hydrogel Admixture | 25 | Participants | ||
| Stage 2: Change From Baseline in the Average Number of Micturition Episodes Per Day | Stage 2: Placebo + Hydrogel Admixture | -1.64 | Standard Error 0.519 | episodes per day | |
| Stage 2: Change From Baseline in the Average Number of Micturition Episodes Per Day | Stage 2: BOTOX® 100U + Hydrogel Admixture | -0.91 | Standard Error 0.514 | episodes per day | |
| Stage 2: Change From Baseline in the Average Number of Micturition Episodes Per Day | Stage 2: BOTOX® 300U + Hydrogel Admixture | -0.86 | Standard Error 0.486 | episodes per day | |
| Stage 2: Change From Baseline in the Average Number of Micturition Episodes Per Day | Stage 2: BOTOX® 400U + Hydrogel Admixture | -1.00 | Standard Error 0.480 | episodes per day | |
| Stage 2: Change From Baseline in the Average Number of Micturition Episodes Per Day | Stage 2: BOTOX® 500U + Hydrogel Admixture | -1.11 | Standard Error 0.492 | episodes per day |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03320850/results